根據 位華爾街分析師的預測,Cordlife Group Limited 的收入預期範圍從 $ 到 $
Cordlife Group Limited 的盈利品質評分是多少?
Cordlife Group Limited 的盈利品質評分為 /。該評分基於盈利能力、增長、現金生成與資本分配以及槓桿四個維度。
Cordlife Group Limited 何時發布財報?
Cordlife Group Limited 的下一份財報預計在 2026-05-28 發布
Cordlife Group Limited 的預期收益是多少?
根據華爾街分析師的預測,Cordlife Group Limited 的預期收益為 $
Cordlife Group Limited 是否超出收益預期?
Cordlife Group Limited 最近的收益為 $, 預期。
關鍵數據
前收市價
$0.1504
開盤價
$0.0901
當日範圍
$0.0901 - $0.0901
52週區間
$0.0689 - $0.1721
交易量
2.1K
平均成交量
21
股息收益率
--
每股盈餘 (TTM)
-0.04
市值
$23.0M
什麼是 CORDLIFE GROUP LIMITED?
Cordlife Group Ltd. is an investment holding company, which engages in the provision of cord blood and cord lining banking services. The firm's principal activities involve investment holding and the provision of cord blood banking services. Its segments include Banking and Diagnostics. The Banking segment comprises of the banking of samples such as cord blood, cord lining and cord tissue. Cord blood, cord lining and cord tissue are collected, processed, and stored in the various laboratories. The Diagnostics segment comprises diagnostic testing such as non-invasive prenatal testing service, newborn metabolic screening, newborn genetic screening, and pediatric vision screening services. Its subsidiaries include Cordlife (Hong Kong) Limited, Cordlife Stem Cell Technology Limited, Healthbaby Biotech (Hong Kong) Co., Limited, Cordlife Technologies Pte. Ltd., CS Cell Technologies Pte. Ltd., Stemlife Berhad, and Shanghai Cordlife Biomedical Research Co., Ltd.